Economic value of investigator-initiated clinical trials


Benefits of Investigator-initiated trials exceed their costs

The Australian Clinical Trials Alliance (ACTA) and the Australian Commission on Safety and Equality in Health Care have published a landmark report outlining the economic benefits of investigator-initiated clinical trials.

The report finds that, if the results of 25 high-impact clinical trials were implemented in 65% of the eligible Australian patient populations:

  • The gross benefit to the Australian economy would be $2 billion through better health outcomes and reduced health service costs
  • An overall return would be $5.80 for every $1 invested

Benefits would exceed costs if the results of these trials were implemented in only 11% of the eligible patient populations.

For every $1 awarded in National Health and Medical Research Council (NHMRC) grants to the 25 trials, a return of $51.10 was achieved.

Just 9% of the $2 billion gross benefit from these trials equals NHMRC funding received by all Australian trial investigator networks between 2004 and 2014.

Download a copy of the full report here.

30 July 2017